Invesco Ltd. Buys 355,581 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Invesco Ltd. raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,064,529 shares of the company's stock after purchasing an additional 355,581 shares during the period. Invesco Ltd. owned approximately 0.54% of Teva Pharmaceutical Industries worth $133,662,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Stifel Financial Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after acquiring an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after purchasing an additional 33,277 shares during the period. Pinnbrook Capital Management LP purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $4,966,000. Asset Management One Co. Ltd. grew its position in Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after purchasing an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $3,340,000. 54.05% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

TEVA has been the subject of several research analyst reports. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded down $0.02 during trading hours on Tuesday, hitting $13.59. The stock had a trading volume of 7,201,630 shares, compared to its average volume of 9,894,315. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market capitalization of $15.40 billion, a price-to-earnings ratio of -9.37, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The stock's 50-day moving average price is $15.64 and its two-hundred day moving average price is $17.76.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.